申请人:GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION
公开号:US20200239452A1
公开(公告)日:2020-07-30
A compound of formula (I) given below or a pharmaceutically acceptable salt of the compound is useful as an IDO/TDO inhibitor. Thus, the compound of formula (I) or the pharmaceutically acceptable salt of the compound can be used as, for example, a therapeutic agent for a disease or a disorder selected from tumor, infectious disease, neurodegenerative disorder, cataract, organ transplant rejection, autoimmune disease, postoperative cognitive impairment, and disease related to women's reproductive health [in the following formula (I), ring A represents an aromatic ring, an aliphatic ring, a heterocyclic ring, or a condensed ring of two or more rings selected from an aromatic ring, an aliphatic ring and a heterocyclic ring; X, R
1
and R
2
represent a substituent on a ring atom constituting ring A; m represents an integer of 0 to 6; X represents, for example, a halogen atom; and R
1
and R
2
are the same or different and are selected from, for example, the group consisting of groups of formula (a) or formula (b); and in the following formula (a) and formula (b), Y is selected from the group consisting of O, S, and Se, Z is selected from the group consisting of O, S, and Se, n represents an integer of 1 to 8, r represents an integer of 1 to 8, s represents an integer of 1 to 8, R
4
represents, for example, —C(═NH)—HN
2
, and R
6
represents, for example, a substituted or unsubstituted aryl group].
以下公式(I)给出的化合物或该化合物的药学上可接受的盐可用作IDO/TDO抑制剂。因此,公式(I)的化合物或该化合物的药学上可接受的盐可用作,例如,用于肿瘤、传染病、神经退行性疾病、白内障、器官移植排斥、自身免疫疾病、术后认知障碍以及与女性生殖健康相关的疾病的治疗剂。在以下公式(I)中,环A代表芳香环、脂环、杂环或两个或更多个选自芳香环、脂环和杂环的缩合环的环;X、R1和R2代表构成环A的环原子上的取代基;m代表0到6的整数;X代表例如卤素原子;R1和R2相同或不同,选自例如由公式(a)或公式(b)组成的基团,而在以下公式(a)和公式(b)中,Y选自O、S和Se组成的基团,Z选自O、S和Se组成的基团,n表示1到8的整数,r表示1到8的整数,s表示1到8的整数,R4代表例如—C(═NH)—HN2,R6代表例如取代或未取代的芳基。